Human pharmacology of 6-[D-alpha-(3-guanylureido)-phenylacetamido]-penicillanic acid (BL-P1654).
BL-P1654 is a new alpha-substituted ureido penicillin which has broad-spectrum activity. Doses of 0.5 and 1.0 g administered by rapid intravenous injection produce mean peak serum concentrations of 40.7 and 80.8 mug/ml, respectively. The same doses administered by 1-h intravenous infusions produce mean peak serum concentrations of 22.6 and 47 mug/ml, respectively. The mean serum concentrations from 1 to 6 h after onset of administration of the drug are the same for both schedules. The mean serum concentration at 6 h after the rapid intravenous injection of 0.5- and 1.0-g doses of BL-P1654 are 3.4 and 5.4 mug/ml, respectively. A dose of 1.0 g every 4 h maintains a serum concentration of about 15 mug/ml. About 50 to 65% of the BL-P1654 is excreted in the urine during the first 6 h.
Bodey
G P
GP
Horikoshi
N
N
Rodriguez
V
V
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood* / Q000737:chemistry; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood* / Q000737:chemistry
D000900:Anti-Bacterial Agents; C009705:BLP 1654; D010397:Penicillanic Acid